A first-of-its-kind drug targeting a fused gene found in many types of cancer was effective in 93 percent of pediatric patients tested, researchers at UT Southwestern’s Simmons Cancer Center announced. The research was published in March 2018 in The Lancet Oncology.
Brayden is a sweet kid who loves to make others happy. Even as he continues to fight ganglioneuroblastoma, he keeps a selfless attitude throughout treatment. His family takes their lead from his perseverance and strength during his diagnosis.